150 likes | 241 Views
Continuous treatment in Finland. Martta Forsell, the Finnish Focal Point . D ata collection in Finland. Voluntary for the treatment centers Separate client questionnaire, not (yet) part of electronic patient record. When entering treatment
E N D
Continuous treatment in Finland Martta Forsell, the Finnish Focal Point Martta Forsell
Data collection in Finland • Voluntary for the treatment centers • Separate client questionnaire, not (yet) part of electronic patient record. • When entering treatment • If client continues in treatment, new questionnaire in January (or springtime..) • Covers an estimated one third of the drug-related treatment • In 2012, 85 units providing drug-related treatment participated in the information collecting, submitting data on 2,688 clients. • No obvious biases Esityksen nimi / Tekijä
Finnish National Treatment Data 2012(n= 2 688) Martta Forsell
Finnish National Treatment Data 2012 (n= 2 688) Esityksen nimi / Tekijä
Finnish National Treatment Data 2012 Esityksen nimi / Tekijä
Length of the treatment (in years since start of treatment) on continuous treatment Esityksen nimi / Tekijä
Length of the treatment as ‘episodes’ (columns) and the OST for clients (black) Esityksen nimi / Tekijä
Renewed questionnaire 2014 onwards The Finnish survey and guidelines needed improving + TDI 3.0 • The questionnaire has been revised 2012-2013 and fully renewed questionnaire will be implemented 2014. • Will be 100% TDI 3.0 compatible • Rethinking on (among others) • ‘primary drug’ on continuous treatment • Continuous treatment in an in-patient facility • OST information • More ‘re-launch’ than ‘fine-tuning’. Overall aims: • better data quality • better coverage • better understanding of the coverage Esityksen nimi / Tekijä
Primarydrug • Defining the primary drug at the start of treatment is straight forward enough • But on continuous treatment the primary problem can change Esityksen nimi / Tekijä
Primarydrug? THEN NOW Primarydrug? Secondarydrug? Route of admistration? Frequency? Intrest on treatmentinputs Intrest on epidemiology Esityksen nimi / Tekijä
PrimarydrugSecondarydrug- route-frequency THEN NOW • Primary & secondarydrug • Route • Frequency Esityksen nimi / Tekijä
Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) • The OST clients are always addicted > opioid as long-standing drug • Frequency is always the very last 30 days (except in-patient..) Esityksen nimi / Tekijä
In-patientclient • Enterstreatment 1.Dec • Questionnaire: use of drugs in Nov • New questionnaire in Jan: use of drugs in Nov • > the copy of previousquestionnaire • Client checks out in Feb • New questionnairein Feb in an out-patientfacility: useof drugs in Jan-Feb Esityksen nimi / Tekijä
Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) • The OST clients are always addicted > opioid as long-standing drug • Frequency is always the very last 30 days (except in-patient..) • NO more in-patient continuous questionnaire Esityksen nimi / Tekijä
Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether in remiss or not) • Which we should put forward as we report the primary drug for the EMCDDA? Esityksen nimi / Tekijä